Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Overview
- Convective clearance – Diagram
- Convective clearance – Definition
- Diffusive clearance – Diagram
- Diffusive clearance – Definition
- Convective and diffusive clearance
- Sieving coefficients
- Comparison of urea clearance
- Clearance: convection vs. diffusion
- Vascular access – Catheter size
- Vascular access – Circuit life
- Vascular access – Patient size
- Vascular access – Example
- Bicarbonate based solutions
- Chemical content of PrismaSol
- Solution choice
- Sites of thrombus formation
- Sites of action of Heparin
- Heparin protocols: benefits and risks
- Citrate anticoagulation
- Evaluation of anticoagulation (1)
- Evaluation of anticoagulation (2)
- ppCRRT ACG side effects
- Complications of citrate (1)
- Complications of citrate (2)
- Metabolic alkalosis
- Complications
- Factors affecting hemodynamics
- Factors affecting hemodynamics – Vasopressors
- pH correction upon Epi effect
- Factors affecting hemodynamics – Vasopressor clearance
- Vascular access – X-ray
- Factors affecting hemodynamics – Vasopressor agents
- Factors affecting hemodynamics – Circuit reaction
- Membranes' compatibility – Biocompatible membranes
- Membranes' compatibility – Bradykinin Release Syndrome
- A safe pH
- Bradykinin Release Syndrome
- Preventing Bradykinin Release Syndrome
- Bradykinin Release Syndrome – Example
- Negating the Bradykinin Factor – Example
- Negating the Bradykinin Factor – Results
- Nutritional losses
- Comparison of total amino acid losses
- D. "known drug characteristics"
- When in doubt, start here…
- Sieving coefficient and protein binding
- Drug prescribing in renal failiure
- Indications for CRRT
- Incidence of AKI
- RIFLE criteria
- Modified pediatric RIFLE
- Creatinine changes and AKI in children
- LOS with AKI-pediatrics
- Unique situations – CRRT
- Stem cell transport: ppCRRT
- Prospective pediatric study
- ppCRRT sepsis study
- ppCRRT [cytokine]% change
- Drug characteristics and intoxication
- Hemodialysis
- Intoxicants amenable to hemodialysis
- Ethylene glycol intoxication
- Vancomycin clearance
- High flux HD for Tegretol intoxication
- HD to convective HF
- Intoxicants amenable to hemofiltration
- In born error of metabolism – Example
- In born error of metabolism – Lab data
- RRT intervention – Example
- RRT intervention – Lab data
- Ammonia clearance – Results
- RRT intervention – From hemodialysis to hemofiltration
- Ammonia clearance – New results
- RRT intervention – Remarks
- Solute clearance in I E M
- When should we begin RRT in AKI?
- Timing of CRRT and mortality in children – A study
- Timing of CRRT and mortality in children – Indication
- Timing of CRRT and mortality in children – Comparison
- Timing of CRRT and mortality in children – Initiation timing
- Timing of CRRT and mortality in children – Remarks
- Timing of initation
- Timing of initiation – cardiac
- What is on the horizon?
- Prismaflex device with HF 20 set
- Carpediem
- NIDUS
- Challenges
- Conclusion
- Thank you
Topics Covered
- Convection clearance vs. diffusive clearance in CRRT
- Vascular access in CRRT
- Drug clearance
- Solutions used in CRRT
- Indications for CRRT (AKI, intoxications, in born error of metabolism)
- Timing of CRRT initiation
Links
Series:
Categories:
Therapeutic Areas:
External Links
Talk Citation
Bunchman, T.E. (2021, March 30). Continuous renal replacement therapy (CRRT) in children [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 22, 2024, from https://doi.org/10.69645/RCNF2881.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Timothy E. Bunchman has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Other Talks in the Series: The Kidney in Health and Disease
Transcript
Please wait while the transcript is being prepared...
0:00
Good morning, this is Dr. Tim Bunchman,
I'm a pediatric nephrologist at Virginia Commonwealth University of Medicine.
My talk today is on CRRT,
which is Continuous Renal Replacement Therapy in children.
0:14
My talk today will talk about things relative to CRRT,
including vascular access, solutions,
anticoagulation, nutrition, drug clearance,
as well as utilization
and timing of CRRT.
0:29
To understand CRRT, one has to understand the terminology.
The concept of convection is a way (by
mass transport) to put a solution that's sterile into the vascular space
(either pre- or post-filter) and to, if you will,
'shove' the solute across the membrane by convection.
0:49
In this next slide,
we have a caricature of the same issue.
Convective clearance is called CVVH,
and you're using a physiologic sterile solution, either post-filter
(which has often happened in Australia) or
pre-filter (which happens mostly in Europe and North America) to shove,
if you will, or move solute across the membrane.
That is CVVH or convective clearance.
1:14
Diffusive clearance is that same model
but you've got dialysate on the outside of the vascular space,
setting up a gradient of which solute comes across, secondary to a gradient concept.
1:27
CVVHD, hemodialysis, peritoneal dialysis,
and a note that I don't have on this slide, SLED
(which is slower low efficiency dialysis), is all diffusion.
The concept of diffusion is that you have a sterile solution across a membrane,
across from the blood space,
that solute clears by a gradient.